# Education, savings, and access-ProAir® HFA offers it all to help you and your patients through the transition

# 30 DAYS until CFC albuterol inhalers banned

#### 15 DAYS

#### **LINKS**

- www.Switch2HFA.com
- www.ProAirHFA.com

Web presentation

- FDA Public Health Advisory on switching patients now
- "For a Smooth Switch and Fast-Acting Relief" Save your qualified patients
- up to \$100 off ProAir HFA\*
- Prescribing Information

\*Up to \$20 off their next 5 prescriptions

## **ProAir HFA offers extensive resources** to support your albuterol CFC-to-HFA switch efforts:

**Pharmacy** Switch **Materials** 



Poster



**Button** 



CFC-to-HFA



Telephone Guide



Switch2HFA.com Web Site

#### **Educational** Resources



**Brochure** 



Instruction Sheets



### Plus, ProAir HFA has the most preferred managed care access<sup>1</sup> and offers high-value support programs:

Savings



Discount Card and Patient Switch Kits



Voucher for Free Inhaler (in lieu of sample)



Teva Assistance Program™



If you have any questions regarding the Teva Assistance Program™ please call us toll-free at (877) 254-1039.

Learn more about how ProAir HFA supports your switch efforts. Watch "For a Smooth Switch and Fast-Acting Relief – Rely on the #1 Albuterol Brand – ProAir HFA," a Web presentation by a leading pulmonary expert.

### Dispense the #1 albuterol inhaler, ProAir HFA - Now FDA-approved for patients as young as 4

ProAir® HFA is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

#### **Important Safety Information**

- Inhaled albuterol sulfate can produce paradoxical bronchospasm that may be life-threatening. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister.
- Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma.
- · ProAir® HFA, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders (especially coronary insufficiency, cardiac arrhythmias, and hypertension), convulsive disorders, hyperthyroidism, and diabetes.
- · Potential drug interactions can occur with beta-blockers, diuretics, digoxin, or monoamine oxidase inhibitors, and tricyclic antidepressants.
- Do not exceed the recommended dose.
- Adverse events, which occurred at an incidence rate of at least 3% with ProAir® HFA. include headache, tachycardia, pain, dizziness, pharyngitis, and rhinitis.

REFERENCES: 1. Business One Technologies. October 1, 2008. 2. IMS Health National Prescription Audit, TRx Data, September 2008.







